181 related articles for article (PubMed ID: 2123821)
1. Generation and characterization of murine antiflagellum monoclonal antibodies that are protective against lethal challenge with Pseudomonas aeruginosa.
Rosok MJ; Stebbins MR; Connelly K; Lostrom ME; Siadak AW
Infect Immun; 1990 Dec; 58(12):3819-28. PubMed ID: 2123821
[TBL] [Abstract][Full Text] [Related]
2. Anti-flagellin IgY antibodies protect against Pseudomonas aeruginosa infection in both acute pneumonia and burn wound murine models in a non-type-specific mode.
Ahmadi TS; Mousavi Gargari SL; Talei D
Mol Immunol; 2021 Aug; 136():118-127. PubMed ID: 34130152
[TBL] [Abstract][Full Text] [Related]
3. Protective efficacy of Pseudomonas aeruginosa type-A flagellin in the murine burn wound model of infection.
Faezi S; Safarloo M; Amirmozafari N; Nikokar I; Siadat SD; Holder IA; Mahdavi M
APMIS; 2014 Feb; 122(2):115-27. PubMed ID: 23758581
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of flagella and flagellin of Pseudomonas aeruginosa as vaccines.
Campodónico VL; Llosa NJ; Grout M; Döring G; Maira-Litrán T; Pier GB
Infect Immun; 2010 Feb; 78(2):746-55. PubMed ID: 19995892
[TBL] [Abstract][Full Text] [Related]
5. Bivalent flagellin immunotherapy protects mice against Pseudomonas aeruginosa infections in both acute pneumonia and burn wound models.
Ahmadi H; Behrouz B; Irajian G; Amirmozafari N; Naghavi S
Biologicals; 2017 Mar; 46():29-37. PubMed ID: 28065582
[TBL] [Abstract][Full Text] [Related]
6. Passive immunisation against Pseudomonas aeruginosa recombinant flagellin in an experimental model of burn wound sepsis.
Faezi S; Sattari M; Mahdavi M; Roudkenar MH
Burns; 2011 Aug; 37(5):865-72. PubMed ID: 21334822
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory activity on bacterial motility and in vivo protective activity of human monoclonal antibodies against flagella of Pseudomonas aeruginosa.
Ochi H; Ohtsuka H; Yokota S; Uezumi I; Terashima M; Irie K; Noguchi H
Infect Immun; 1991 Feb; 59(2):550-4. PubMed ID: 1898908
[TBL] [Abstract][Full Text] [Related]
8. Antibodies raised against divalent type b flagellin and pilin provide effective immunotherapy against Pseudomonas aeruginosa infection of mice with burn wounds.
Saffari M; Behbood S; Irajian G; Khorshidi A; Moniri R; Behrouz B
Biologicals; 2017 Jan; 45():20-26. PubMed ID: 27836582
[TBL] [Abstract][Full Text] [Related]
9. Functionally active monoclonal antibody that recognizes an epitope on the O side chain of Pseudomonas aeruginosa immunotype-1 lipopolysaccharide.
Stoll BJ; Pollack M; Young LS; Koles N; Gascon R; Pier GB
Infect Immun; 1986 Sep; 53(3):656-62. PubMed ID: 2427453
[TBL] [Abstract][Full Text] [Related]
10. Flagellin and pilin immunization against multi-drug resistant Pseudomonas aeruginosa protects mice in the burn wound sepsis model.
Korpi F; Hashemi FB; Irajian G; Fatemi MJ; Laghaei P; Behrouz B
Immunol Lett; 2016 Aug; 176():8-17. PubMed ID: 27210422
[TBL] [Abstract][Full Text] [Related]
11. A trivalent vaccine consisting of "flagellin A+B and pilin" protects against Pseudomonas aeruginosa infection in a murine burn model.
Hashemi FB; Behrouz B; Irajian G; Laghaei P; Korpi F; Fatemi MJ
Microb Pathog; 2020 Jan; 138():103697. PubMed ID: 31465785
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the immune responses following co-administration of PilQ and type b-flagellin from Pseudomonas aeruginosa in the burn mouse model.
Bakht Azad S; Nikokar I; Faezi S; Rasooly S; Mahdavi M
Microb Pathog; 2018 Oct; 123():426-432. PubMed ID: 30075242
[TBL] [Abstract][Full Text] [Related]
13. Therapy with anti-flagellin A monoclonal antibody limits Pseudomonas aeruginosa invasiveness in a mouse burn wound sepsis model.
Barnea Y; Carmeli Y; Neville LF; Kahel-Reifer H; Eren R; Dagan S; Navon-Venezia S
Burns; 2009 May; 35(3):390-6. PubMed ID: 18951715
[TBL] [Abstract][Full Text] [Related]
14. Isolation and characterization of a human monoclonal antibody that recognizes epitopes shared by Pseudomonas aeruginosa immunotype 1, 3, 4, and 6 lipopolysaccharides.
Lang AB; Fürer E; Larrick JW; Cryz SJ
Infect Immun; 1989 Dec; 57(12):3851-5. PubMed ID: 2509371
[TBL] [Abstract][Full Text] [Related]
15. Protection against infection with Pseudomonas aeruginosa by passive transfer of monoclonal antibodies to lipopolysaccharides and outer membrane proteins.
Sawada S; Suzuki M; Kawamura T; Fujinaga S; Masuho Y; Tomibe K
J Infect Dis; 1984 Oct; 150(4):570-6. PubMed ID: 6436393
[TBL] [Abstract][Full Text] [Related]
16. Systematic generation of antigen specific human monoclonal antibodies with therapeutical activities using active immunization.
Lang AB; Fürer E; Senyk G; Larrick JW; Cryz SJ
Hum Antibodies Hybridomas; 1990; 1(2):96-103. PubMed ID: 2129420
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of antibodies against the N-terminal of Pseudomonas aeruginosa flagellin for treating infections in a murine burn wound model.
Barnea Y; Carmeli Y; Gur E; Kuzmenko B; Gat A; Neville LF; Eren R; Dagan S; Navon-Venezia S
Plast Reconstr Surg; 2006 Jun; 117(7):2284-91. PubMed ID: 16772930
[TBL] [Abstract][Full Text] [Related]
18. Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11.
Horn MP; Zuercher AW; Imboden MA; Rudolf MP; Lazar H; Wu H; Hoiby N; Fas SC; Lang AB
Antimicrob Agents Chemother; 2010 Jun; 54(6):2338-44. PubMed ID: 20308370
[TBL] [Abstract][Full Text] [Related]
19. Protection against Pseudomonas aeruginosa infection by passive transfer of anti-flagellar serum.
Drake D; Montie TC
Can J Microbiol; 1987 Sep; 33(9):755-63. PubMed ID: 3121159
[TBL] [Abstract][Full Text] [Related]
20. Establishment of stable cell lines producing anti-Pseudomonas aeruginosa monoclonal antibodies and their protective effects for the infection in mice.
O'Oka H; Chonan E; Mizutani K; Fukuda T; Kuroiwa Y; Ono Y; Shigeta S
Microbiol Immunol; 1992; 36(12):1305-16. PubMed ID: 1287405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
